Abstract
AbstractObjectivesTo describe the standardized body mass index (z-BMI) trajectory of children and adolescents admitted to a psychiatric reference center in Mexico City according to their diagnosis and medication use. A secondary objective was to compare z-BMI between antipsychotic users and non-users.MethodsDiagnosis, prescribed medications, serial heights, and weights were collected from the medical records.ResultsThe median baseline z-BMI of the 129 analyzed cases was 0.88 (IQR: 0 -1.92), and the overweight/obesity prevalence was 46.8%. At the end of follow-up (median, 50.3 weeks), they had a median change in z-BMI of -0.09 (IQR: - 0.68 -0.42). New long-term users of antipsychotics (n = 29) had an increase in their z-BMI, in contrast to never-users (median difference 0.73, p = 0.01) and to previous users (median difference 0.92, p = 0.047). The 59 subjects with excessive weight at admission had a median change in z -BMI of -0.39 (IQR: - 0.81--0.04). Among patients with excessive weight and depression, a greater decrease in z-BMI was observed in sertraline users (n = 13) compared with fluoxetine users (n = 15) (median -0.65 vs. 0.21, p<0.001).ConclusionsNew long-term users of antipsychotics increased their z-BMI significantly. Patients with depressive disorders and obesity on sertraline therapy tend to decrease their z-BMI.
Publisher
Cold Spring Harbor Laboratory
Reference32 articles.
1. Instituto Nacional de Salud Pública. Datos abiertos de México-INSP-Instituciones [Internet]. [cited 2023 May 17]. Available from: datos.gob.mx/busca/dataset/encuesta-nacional-de-salud-y-nutrición-continua-covid-19-2020-modulo-nutricion
2. Chao AM , Wadden TA , Berkowitz RI . Obesity in Adolescents with Psychiatric Disorders. Vol. 21, Current Psychiatry Reports. Current Medicine Group LLC 1; 2019.
3. Ringen PA , Engh JA , Birkenaes AB , Dieset I , Andreassen OA . Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes and interventions. Front Psychiatry. 2014;5(SEP).
4. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies;Adv Ther,2021
5. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines;Circulation. NLM (Medline),2023